PT1811988E - Utilização de acetil l-carnitina em combinação com propionilo l-carnitina e sildenafil para o tratamento da disfunção eréctil - Google Patents

Utilização de acetil l-carnitina em combinação com propionilo l-carnitina e sildenafil para o tratamento da disfunção eréctil Download PDF

Info

Publication number
PT1811988E
PT1811988E PT05798477T PT05798477T PT1811988E PT 1811988 E PT1811988 E PT 1811988E PT 05798477 T PT05798477 T PT 05798477T PT 05798477 T PT05798477 T PT 05798477T PT 1811988 E PT1811988 E PT 1811988E
Authority
PT
Portugal
Prior art keywords
carnitine
therapy
acetyl
propionyl
sildenafil
Prior art date
Application number
PT05798477T
Other languages
English (en)
Portuguese (pt)
Inventor
Giorgio Cavallini
Aleardo Koverech
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of PT1811988E publication Critical patent/PT1811988E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT05798477T 2004-11-11 2005-10-19 Utilização de acetil l-carnitina em combinação com propionilo l-carnitina e sildenafil para o tratamento da disfunção eréctil PT1811988E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000561A ITRM20040561A1 (it) 2004-11-11 2004-11-11 Uso della acetil l-carnitina in combinazione con propionil l-carnitina e sildenafil per il trattamento della disfunzione erettile.

Publications (1)

Publication Number Publication Date
PT1811988E true PT1811988E (pt) 2010-04-08

Family

ID=35501123

Family Applications (1)

Application Number Title Priority Date Filing Date
PT05798477T PT1811988E (pt) 2004-11-11 2005-10-19 Utilização de acetil l-carnitina em combinação com propionilo l-carnitina e sildenafil para o tratamento da disfunção eréctil

Country Status (16)

Country Link
US (1) US8003652B2 (https=)
EP (1) EP1811988B1 (https=)
JP (1) JP5080263B2 (https=)
KR (1) KR101455275B1 (https=)
AT (1) ATE456950T1 (https=)
CA (1) CA2585654C (https=)
CY (1) CY1110239T1 (https=)
DE (1) DE602005019251D1 (https=)
DK (1) DK1811988T3 (https=)
ES (1) ES2339265T3 (https=)
IT (1) ITRM20040561A1 (https=)
MX (1) MX2007005518A (https=)
PL (1) PL1811988T3 (https=)
PT (1) PT1811988E (https=)
SI (1) SI1811988T1 (https=)
WO (1) WO2006050794A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010222347A (ja) * 2009-02-24 2010-10-07 Daiichi Sankyo Healthcare Co Ltd Ｐｄｅ５阻害剤及びカルニチンを含有する医薬組成物
WO2012000634A1 (de) 2010-06-29 2012-01-05 Georg Bambach Pharmazeutische zusammensetzung zur behandlung von erektiler dysfunktion
WO2018070971A1 (ru) * 2016-10-10 2018-04-19 Товарыство З Обмэжэною Видповидальнистю Науково-Выробныча Фирма "Микрохим" Фармацевтическая композиция в форме оромукозного спрея для лечения эректильной дисфункции и легочной артериальной гипертензии

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE462791T1 (de) 1999-08-13 2010-04-15 Deutsches Krebsforsch Parvovirus ns1 varianten
IT1306722B1 (it) * 1999-10-08 2001-10-02 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di disfunzionicircolatorie, comprendente derivati della l-carnitina ed estratti di
JP2001233770A (ja) * 2000-02-23 2001-08-28 Dountsuendorufaa Udo 勃起機能不全治療用の経口薬の組合わせ
ITRM20010621A1 (it) * 2001-10-18 2003-04-18 Aldo Fassi Sali metallici non igroscopici e idrosolubili di alcanoil l-carnitine, integratori dietetici che li contengono e kit dietetici, per contrast
ITRM20010708A1 (it) * 2001-12-04 2003-06-04 Sigma Tau Ind Farmaceuti Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile.
ITRM20020620A1 (it) * 2002-12-13 2004-06-14 Sigma Tau Ind Farmaceuti Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa.

Also Published As

Publication number Publication date
EP1811988A1 (en) 2007-08-01
CY1110239T1 (el) 2015-01-14
MX2007005518A (es) 2007-05-18
JP5080263B2 (ja) 2012-11-21
KR20070085961A (ko) 2007-08-27
DK1811988T3 (da) 2010-05-17
ES2339265T3 (es) 2010-05-18
CA2585654A1 (en) 2006-05-18
EP1811988B1 (en) 2010-02-03
SI1811988T1 (sl) 2010-10-29
WO2006050794A1 (en) 2006-05-18
PL1811988T3 (pl) 2010-07-30
ATE456950T1 (de) 2010-02-15
US8003652B2 (en) 2011-08-23
DE602005019251D1 (de) 2010-03-25
CA2585654C (en) 2013-04-02
KR101455275B1 (ko) 2014-10-27
JP2008531466A (ja) 2008-08-14
US20080090906A1 (en) 2008-04-17
ITRM20040561A1 (it) 2005-02-11

Similar Documents

Publication Publication Date Title
KR20010023745A (ko) 항간질 화합물을 포함하는 진통제 조성물 및 이의 사용 방법
JP5788527B2 (ja) キナーゼ阻害剤の副作用低減剤
ES2385935T3 (es) Reducción de mareos, un efecto secundario asociado con la terapia de pirfenidona.
JPWO2004019928A1 (ja) 肝疾患治療剤
ES2535401T3 (es) Composiciones para el tratamiento de enfermedades neoplásicas
US20170319519A1 (en) Combination for the treatment of conditions involving muscular pain
CN104812415A (zh) 药物组合
TWI341728B (en) Combinations comprising epothilones and anti-metabolites
PT1811988E (pt) Utilização de acetil l-carnitina em combinação com propionilo l-carnitina e sildenafil para o tratamento da disfunção eréctil
EP1569635B1 (en) Use of carnitines for the prevention and/or treatment of disorders caused by the andropause
HU229214B1 (hu) Propionil-L-karnitint és további hatóanyagokat tartalmazó kombinációs készítmény alkalmazása merevedési zavar kezelésére
BR112021015682A2 (pt) Combinação de silício e magnésio para a prevenção e tratamento contra cãibras musculares
US7776913B2 (en) Carnitines for treating or preventing disorders caused by andropause
EP2897606A1 (en) Plant phenols and their use in the treatment or prevention of eosinophilic esophagitis
CN101467992A (zh) L-肉碱用于治疗心血管疾病的用途
ES2203115T3 (es) Composicion que comprende ketanserina y l-carnitina para el tratamiento del sindrome de dolor local cronico.
JP2006516030A (ja) Ｃｏｐｄ及びその他の疾患に罹患した患者の状態を改善するための組成物及び方法
ES2981316T3 (es) Tratamiento de fibrosis con inositol
CN102349923B (zh) L-肉碱和葡萄糖治疗心血管疾病的应用
ES2425045T3 (es) Acetil-L-carnitina para la prevención de la neuropatía diabética periférica dolorosa
WO2017100324A1 (en) Combination therapy for treating female hypoactive sexual desire disorders
WO2026028044A1 (en) A bioactive peptide composition
KR0128705B1 (ko) 두통 예방 및 치료제 조성물
US20050059741A1 (en) Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxygenase-1